Why the study?
Clopidogrel is widely used in STEMI patients but leads to sub-optimal platelet inhibition in up to one-third of treated patients.
Does a CYP2C19 genotype-guided strategy reduce combined ischemic and bleeding outcomes in STEMI patients compared to standard clopidogrel treatment?
Does a CYP2C19 genotype-guided strategy reduce combined ischemic and bleeding outcomes in STEMI patients compared to standard clopidogrel treatment?
A CYP2C19 genotype-guided strategy for P2Y12 inhibitor selection significantly reduces ischemic and bleeding outcomes in STEMI patients undergoing PCI compared to standard clopidogrel therapy.
No takes yet. Share an insight, caveat, or question.
Genotype-guided P2Y12 selection feasible in STEMI; leaves open whether it improves outcomes in larger trials.
Al‐Rubaish et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: